Pedro C. Barata MD
Assistant Professor, Tulane Medical School, Department of Internal Medicine, Section of Hematology and Medical Oncology, New Orleans, Louisiana
Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. After completion of his fellowship, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata moved to Tulane University to continue his clinical and research work in the GU field and to help expand the genitourinary program offered at Tulane Cancer Center, with a focus on clinical trials. Dr Barata currently leads the kidney and bladder cancer program at Tulane University.
Dr. Barata has authored or co-authored more than 50 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 650 scientific citations. In addition, he has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018).
He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal of Global Oncology and is a panel reviewer for Department of Defense Congressionally Directed Medical Research Programs (CDMRP) for genitourinary tumors.
Dr. Barata has authored or co-authored more than 50 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 650 scientific citations. In addition, he has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018).
He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal of Global Oncology and is a panel reviewer for Department of Defense Congressionally Directed Medical Research Programs (CDMRP) for genitourinary tumors.